Biomedical Engineering Reference
In-Depth Information
Table 10.3
Published Clinical Studies on ALA- and MAL-PDT for Superfi cial Basal Cell Carcinoma
Light Source
(Wavelength
in nm)
Incubation
Period (hr)
# Lesions Treated
(# Patients)
Reference
ALA Preparation
Location of sBCC
Response Rate
Follow-up (mo)
Kennedy (138) (1990)
20% Emulsion
Not specifi ed
3
80 Lesions
Slide projector with
a cutoff fi lter at
600 nm
90% CR
2-3
Calzavara-Pinton
(132) (1995)
20% emulsion
ALA-PDT
repeated EOD
until clinical
disappearance
Head, trunk, and
limbs
6-8 occluded
23 lesions
Argon dye laser
(630)
91% CR
24-36
Fijan (264) (1995)
1× ALA-PDT in
combination with
desferrioxamine
(no lesion
preparation
specifi ed),
repeated after
3-6 mo if required
Face, scalp, trunk,
and extremities
Not specifi ed
34 (32)
Halogen lamp with
a red fi lter
88% CR after 1
treatment, 97%
after 2 treatments
20
Wennberg (265)
(1996)
20% emulsion
1× ALA-PDT
Not specifi ed
3 Occluded
190 (37)
Filtered xenon lamp
(620-670 nm)
92% CR
6
Fink-Puches (131)
(1998)
20% Emulsion
1× ALA-PDT
Face, scalp, neck,
trunk (65 lesions),
and lower
extremity
4 Occluded
95 (47)
UV-A or full-
spectrum visible
light, >515, >570,
or >610 nm)
Initial response
(2-4 wk) : 86%
CR, recurrence
rate of 44% after
median of 19 mo
Median of 19 mo
Haller (266) (2000)
20% cream Routine
2× ALA-PDT,
7 days apart
Face, trunk, and
limbs
3-4 occluded
26 (6)
Red light
(630 ± 15 nm)
1-2 mo lesion CR:
100%; 1 lesion
recurred at 16 mo
Median of 27 mo
